



Apr 14th, 2:35 PM - 3:35 PM

# Analysis of Coronavirus Protease Inhibitors as Potential Therapeutics

Katherine Houser, '07

*Illinois Wesleyan University*

Susan Baker, Faculty Advisor

*Loyola University*

Follow this and additional works at: <http://digitalcommons.iwu.edu/jwprc>

Katherine Houser, '07 and Susan Baker, Faculty Advisor, "Analysis of Coronavirus Protease Inhibitors as Potential Therapeutics" (April 14, 2007). *John Wesley Powell Student Research Conference*. Paper 38.  
<http://digitalcommons.iwu.edu/jwprc/2007/posters2/38>

This Event is brought to you for free and open access by The Ames Library, the Andrew W. Mellon Center for Curricular and Faculty Development, the Office of the Provost and the Office of the President. It has been accepted for inclusion in Digital Commons @ IWU by the faculty at Illinois Wesleyan University. For more information, please contact [digitalcommons@iwu.edu](mailto:digitalcommons@iwu.edu).  
©Copyright is owned by the author of this document.

Poster Presentation P40

**ANALYSIS OF CORONAVIRUS PROTEASE INHIBITORS AS  
POTENTIAL THERAPEUTICS**

Katherine Houser and Susan Baker\*

Biology Department, Illinois Wesleyan University

Department of Microbiology and Immunology, Loyola University

SARS-HCoV, or Severe Acute Respiratory Syndrome, is a novel human coronavirus that appeared within China in 2003. To date there are no vaccines or antiviral drugs able to either halt or prevent an infection by the virus. As part of an ongoing study, experiments were designed to develop and assess broad-spectrum antiviral drugs against several human and murine coronaviruses. The research involved testing antiviral drugs against the mouse coronavirus MHV. These drugs, which were composed of branched organic compounds, targeted the active site of one of the two proteases of the murine coronavirus, 3CLPro, halting the enzymatic activity resulting in viral inhibition. The drugs had already been proven effective in purified protease samples, but had yet to be tested in living cells. Thirty-five drugs were tested, and while twenty-two displayed no viral inhibition and five exhibited cell toxicity, eight drugs were shown to strongly inhibit viral replication. The drugs that were found to be effective at inhibiting the viral replication will continue on to be tested against SARS-HCoV in the Biosafety Level 3 lab at UIC. The effective drugs were also used further in order to screen for drug resistant variants of the virus. These mutants can then be sequenced so that the drugs can be improved and the resistance avoided.